- Home
- MCS vs DSGN Comparison
MCS vs DSGN Comparison
Compare MCS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- DSGN
- Stock Information
- Founded
- MCS 1935
- DSGN 2017
- Country
- MCS United States
- DSGN United States
- Employees
- MCS N/A
- DSGN N/A
- Industry
- MCS Movies/Entertainment
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- DSGN Health Care
- Exchange
- MCS Nasdaq
- DSGN Nasdaq
- Market Cap
- MCS 430.2M
- DSGN 430.6M
- IPO Year
- MCS N/A
- DSGN 2021
- Fundamental
- Price
- MCS $14.95
- DSGN $7.30
- Analyst Decision
- MCS Strong Buy
- DSGN Hold
- Analyst Count
- MCS 4
- DSGN 1
- Target Price
- MCS $24.00
- DSGN $6.00
- AVG Volume (30 Days)
- MCS 243.4K
- DSGN 395.4K
- Earning Date
- MCS 10-31-2025
- DSGN 11-05-2025
- Dividend Yield
- MCS 2.09%
- DSGN N/A
- EPS Growth
- MCS N/A
- DSGN N/A
- EPS
- MCS 0.25
- DSGN N/A
- Revenue
- MCS $712,239,000.00
- DSGN N/A
- Revenue This Year
- MCS $11.41
- DSGN N/A
- Revenue Next Year
- MCS $4.83
- DSGN N/A
- P/E Ratio
- MCS $62.49
- DSGN N/A
- Revenue Growth
- MCS 6.27
- DSGN N/A
- 52 Week Low
- MCS $12.85
- DSGN $2.60
- 52 Week High
- MCS $23.16
- DSGN $7.93
- Technical
- Relative Strength Index (RSI)
- MCS 51.38
- DSGN 57.17
- Support Level
- MCS $14.85
- DSGN $6.81
- Resistance Level
- MCS $16.18
- DSGN $7.93
- Average True Range (ATR)
- MCS 0.61
- DSGN 0.63
- MACD
- MCS 0.05
- DSGN 0.04
- Stochastic Oscillator
- MCS 60.32
- DSGN 70.62
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.